Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Boehringer Ingelheim Acquires Nerio Therapeutics, Securing Novel Immune Checkpoint Inhibitor

NextEdge Admin

31 Jul 2024

2 min 42 sec

immune checkpoint inhibitors,Oncology,Genomics,Boehringer Ingelheim

Boehringer Ingelheim is enhancing its immuno-oncology pipeline with the acquisition of Nerio Therapeutics Inc. for up to USD 1.3 billion. This strategic move aims to develop Nerio's innovative preclinical program as a key component of its immuno-oncology portfolio, ultimately improving cancer patient outcomes.

Nerio’s small molecules inhibit protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which function as immune checkpoints. By inhibiting PTPN1/2, these molecules can activate the immune system to target cancer cells.

While current immune checkpoint inhibitors have revolutionized cancer treatment, they do not benefit all patients. Boehringer Ingelheim is dedicated to expanding the reach of immuno-oncology benefits through a comprehensive portfolio of therapies designed to boost the immune system's ability to fight cancer. Nerio’s inhibitors are poised to be a significant addition, potentially effective as single-agent therapies and in combination with other in-house cancer treatments.

Paola Casarosa, Member of the Board of Managing Directors at Boehringer Ingelheim, emphasized the importance of this acquisition: “Securing the rights to Nerio Therapeutics' novel checkpoint inhibitors creates a broad panel of exciting new cancer treatment combination opportunities. This brings us a major step closer to our vision of transforming the lives of people living with cancer.”

Sanford Madigan, partner at Avalon BioVentures and co-founder and CEO of Nerio Therapeutics, added, “We believe Nerio’s small molecule PTPN1/N2 inhibitors have superior drug-like properties and provide a first-in-class opportunity. We are excited to expand Boehringer Ingelheim’s pipeline and commend their commitment to unlocking the full potential of our compounds and their unique approach to fighting cancer.”

This acquisition strengthens Boehringer Ingelheim’s oncology pipeline, positioning it to offer transformative cancer care through smart therapeutic combinations.